✦ LIBER ✦

A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma

✍ Scribed by Peter J. Hosein; Michael D. Craig; Martin S. Tallman; Ralph V. Boccia; Brian L. Hamilton; Jonathan J. Lewis; Izidore S. Lossos

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 850 KB
Volume: 87
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.22232

No coin nor oath required. For personal study only.

✦ Synopsis

ABVD: doxorubicin,

📜 SIMILAR VOLUMES

Phase II study of oxaliplatin in patient

Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma

✍ Yasuhiro Oki; Peter McLaughlin; Barbara Pro; Fredrick B. Hagemeister; Archie Ble 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB 👁 2 views

2′ deoxycoformycin (pentostatin) for ref

2′ deoxycoformycin (pentostatin) for refractory non-Hodgkin's lymphoma: A calgb phase II study

✍ Duggan, D. B. ;Anderson, J. R. ;Dillman, R. ;Case, D. ;Gottlieb, A. J. 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 330 KB

## Abstract Seventy‐six eligible patients with relapsed or refractory non‐Hodgkin's lymphoma (NHL) were treated with 2′‐deoxycoformycin (pentostatin) at a dose of 4 mg/m^2^ intravenously weekly for three weeks and then every other week for a minimum of five total treatments. All patients had measur

Cladribine in the treatment of advanced

Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma

✍ Anil Tulpule; Gary Schiller; Laura A. Harvey-Buchanan; Myung Lee; Byron M. Espin 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 2 views

## BACKGROUND. Cladribine (2-chlorodeoxyadenosine) is a purine nucleoside analog with cytotoxic activity against both resting and proliferating cells. Clinical studies with cladribine have reported antitumor activity against various hematologic malignancies.

Ifosfamide, etoposide, cytarabine, and m

Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

✍ Aspasia Stamatoullas; Christophe Fruchart; Dominique Bastit; Dominique Boulet; M 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 567 KB

Efficacy and safety of clofarabine in re

Efficacy and safety of clofarabine in relapsed and/or refractory non-hodgkin lymphoma, including rituximab-refractory patients

✍ Chadi Nabhan; Nancy Davis; Jacob D. Bitran; Angel Galvez; Walter Fried; Kathy To 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB 👁 2 views

Phase II trial of etoposide and cisplati

Phase II trial of etoposide and cisplatin in patients with refractory and relapsed non-Hodgkin's lymphoma: Cancer and leukemia group B study 8351

✍ Rybak, Mary Ellen ;Anderson, James ;Kaplan, Richard ;Budman, Daniel R. ;Vincigue 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB

## Abstract A phase‐II study was conducted by the Cancer and Leukemia Group B (CALGB) in patients with refractory and relapsed non‐Hodgkin's lymphoma (NHL) to assess the activity of the combination of etoposide and cisplatin. Sixty‐five patients were entered on study, and 51 patients were evaluated